<resources>
    <string name="space" translatable="false"> </string>
    <string name="app_name">MedGuidelines</string>
    <string name="childPughTitle">Child-Pugh Score</string>
    <string name="aDropTitle" translatable="false">A-drop</string>
    <string name="colorectalTNMTitle">Colorectal cancer TNM classification (8th)</string>
    <string name="acuteTonsillitisAlgorithmTitle">Acute tonsillitis/pharyngitis algorithm</string><!-- (Journal of the Japanese Association for Infectious Diseases, 2019; 93: 623–642.)-->
    <string name="indexScreen_searchbar">Search</string>
    <string name="bilirubinGrade1" translatable="false">&lt; 2</string>
    <string name="bilirubinGrade2" translatable="false">2–3</string>
    <string name="bilirubinGrade3" translatable="false">&gt; 3</string>
    <string name="albuminGrade1" translatable="false">&gt; 3.5</string>
    <string name="albuminGrade2" translatable="false">2.8–3.5</string>
    <string name="albuminGrade3" translatable="false">&lt; 2.8</string>
    <string name="ptGrade1" translatable="false">&lt; 1.7</string>
    <string name="ptGrade2" translatable="false">1.7–2.3</string>
    <string name="ptGrade3" translatable="false">&gt; 2.3</string>
    <string name="ascitesGrade1">absent</string>
    <string name="ascitesGrade2">slight</string>
    <string name="ascitesGrade3">moderate</string>
    <string name="encephalopathyGrade1">none</string>
    <string name="encephalopathyGrade2">grade 1–2</string>
    <string name="encephalopathyGrade3">grade 3–4</string>
    <string name="ageTitle">Age: Male &gt;= 70, Female &gt;= 75</string>
    <string name="dehydrationTitle">BUN &gt; 21 mg/dL or dehydration</string>
    <string name="respirationTitle">SpO&lt;sub>2&lt;/sub> &lt; 90% or PaO&lt;sub>2&lt;/sub> &lt; 60 mmHg</string>
    "
    <string name="orientationTitle">Consciousness disorder</string>
    <string name="pressureTitle">Systolic pressure &lt; 90 mmHg</string>"
    <string name="bilirubinTitle">Bilirubin (mg/dL)</string>
    <string name="bilirubinTitleNote">Serum total bilirubin</string>
    <string name="albuminTitle">Albumin (g/dL)</string>
    <string name="albuminTitleNote">Albumin (g/dL)</string>
    <string name="ptTitle">Prothrombin (INR)</string>
    <string name="ptTitleNote">Prothrombin (INR)</string>
    <string name="ascitesTitle">Ascites</string>
    <string name="ascitesTitleNote">Ascites</string>
    <string name="encephalopaphyTitle">Encephalopathy grade</string>
    <string name="encephalopaphyTitleNote">&lt;b>Grade 1&lt;/b>: Trivial lack of awareness, Euphoria or anxiety, Shortened attention span, Impairment of addition or subtraction, Altered sleep rhythm. \n&lt;b>Grade 2&lt;/b>: Lethargy or apathy, Disorientation for time, Obvious personality change, Inappropriate behavior, Dyspraxia, Asterixis. \n&lt;b>Grade 3&lt;/b>: Somnolence to semistupor, Responsive to stimuli, Confused, Gross disorientation, Bizarre behavior. \n&lt;b>Grade 4&lt;/b>: Coma</string>
    <string name="adropLiteralScoreMild">Mild, outpatient care</string>
    <string name="adropLiteralScoreModerate">Moderate, outpatient or hospital care</string>
    <string name="adropLiteralScoreSevere">Severe, hospital care</string>
    <string name="adropLiteralScoreMostSevere">Most severe, ICU admission</string>
    <string name="TFactorTitle">T factor</string>
    <string name="NFactorTitle">N factor</string>
    <string name="MFactorTitle">M factor</string>
    <string name="Tis" translatable="false">Tis</string>
    <string name="T1" translatable="false">T1</string>
    <string name="T1a" translatable="false">T1a</string>
    <string name="T1b" translatable="false">T1b</string>
    <string name="T1c" translatable="false">T1c</string>
    <string name="T2" translatable="false">T2</string>
    <string name="T3" translatable="false">T3</string>
    <string name="T4a" translatable="false">T4a</string>
    <string name="T4b" translatable="false">T4b</string>
    <string name="N0" translatable="false">N0</string>
    <string name="N1a" translatable="false">N1a</string>
    <string name="N1b" translatable="false">N1b</string>
    <string name="N1c" translatable="false">N1c</string>
    <string name="N2a" translatable="false">N2a</string>
    <string name="N2b" translatable="false">N2b</string>
    <string name="M0" translatable="false">M0</string>
    <string name="M1a" translatable="false">M1a</string>
    <string name="M1b" translatable="false">M1b</string>
    <string name="M1c" translatable="false">M1c</string>
    <string name="TfactorTitleNoteColorectalCancer">&lt;b>Tis&lt;/b>: intramucosal\n&lt;b>T1&lt;/b>: submucosa\n&lt;b>T2&lt;/b>: muscularis propria\n&lt;b>T3&lt;/b>: pericolorectal\n&lt;b>T4a&lt;/b>: perforate visceral peritoneum\n&lt;b>T4b&lt;/b>: invade or adherent to adjacent organs or structure.</string>
    <string name="NfactorTitleNoteColorectalCancer">&lt;b>N1a&lt;/b>: 1, &lt;b>N1b&lt;/b>: 2–3 regional nodes, &lt;b>N1c&lt;/b>: Tumour deposit(s), i.e. satellites,* in the subserosa, or in non‐peritonealised pericolic or perirectal soft tissue without regional lymph node metastatic disease\n&lt;b>N2a&lt;/b>: 4–6, &lt;b>N2b&lt;/b>: 7 or more regional nodes.</string>
    <string name="MfactorTitleNoteColorectalCancer">&lt;b>M1a&lt;/b>: one organ without peritoneal metastases\n&lt;b>M1b&lt;/b>: more than one organ\n&lt;b>M1c&lt;/b>: to the peritoneum with or without other organ involvement.</string>
    <string name="TfactorTitleNotePancreaticCancer">&lt;b>Tis&lt;/b>:Carcinoma in situ: includes high-grade pancreatic intraepithelial neoplasia (PanIn-3), intraductal papillary mucinous neoplasm with high-grade dysplasia, intraductal tubulopapillary neoplasm with high-grade dysplasia, and mucinous cystic neoplasm with high-grade dysplasia\n&lt;b>T1a&lt;/b>: Tumor limited to the pancreas, ≤0.5 cm\n&lt;b>T1b&lt;/b>: >0.5 cm and &lt; 1 cm\n&lt;b>T1c&lt;/b>: 1–2 cm\n&lt;b>T2&lt;/b>: >2 cm and ≤4 cm\n&lt;b>T3&lt;/b>: >4 cm\n&lt;b>T4&lt;/b>: Tumor involves the celiac axis, superior mesenteric artery, and/or common hepatic artery, regardless of size</string>
    <string name="NfactorTitleNotePancreaticCancer">&lt;b>N1&lt;/b>: 1-3 regional lymph nodes\n&lt;b>N2&lt;/b>: ≥4 regional lymph nodes</string>
    <string name="MfactorTitleNotePancreaticCancer">&lt;b>M1&lt;/b>: Distant metastasis</string>
    <string name="presence">Presence</string>
    <string name="absence">Absence</string>
    <string name="mclsaacFever1" translatable="false">&lt; 38°C</string>
    <string name="mclsaacFever2" translatable="false">≥ 38°C</string>
    <string name="temperatureTitle">Temperature >38°C</string>
    <string name="coughTitle">Cough</string>
    <string name="cervicalNodesTitle">Swollen, tender anterior cervical nodes</string>
    <string name="tonsillarTitle">Tonsillar swelling or exudate</string>
    <string name="mclsaacAge1">3–14 years</string>
    <string name="mclsaacAge2">15–44 years</string>
    <string name="mclsaacAge3">≥45 years</string>
    <string name="mclsaacAgeTitle">Age</string>
    <string name="tonsillitisRedFlag1">Airway obstruction</string>
    <string name="tonsillitisRedFlag2">Difficulty swallowing/drooling</string>
    <string name="tonsillitisRedFlag3">Muffled speech</string>
    <string name="tonsillitisRedFlag4">Severe respiratory distress</string>
    <string name="tonsillitisRedFlag5">Sepsis</string>
    <string name="none">None</string>
    <string name="tonsillitisRedFlagTitle" translatable="false">Red flag</string>
    <string name="followup">Follow up</string>
    <string name="antigenTest">Bacterial antigen or culture test</string>
    <string name="antibioticsAMPC">Antibiotics (AMPC recommended)</string>
    <string name="hospitalCare">Hospital care</string>
    <string name="needSpecialistExamination">Need specialist examination</string>
    <string name="yes">Yes</string>
    <string name="no">No</string>
    <string name="bloodGasAnalysisTitle">Blood Gas Analysis</string>
    <string name="acutePancreatitisTitle">Severity of Acute Pancreatitis</string>
    <string name="ph" translatable="false">pH</string>
    <string name="po2" translatable="false">pO&lt;sub>2&lt;/sub></string>
    <string name="pco2" translatable="false">pCO&lt;sub>2&lt;/sub></string>
    <string name="hco3" translatable="false">HCO&lt;sub>3&lt;/sub></string>
    <string name="na" translatable="false">Na&lt;sup>+&lt;/sup></string>
    <string name="cl" translatable="false">Cl&lt;sup>-&lt;/sup></string>
    <string name="k" translatable="false">K&lt;sup>+&lt;/sup></string>
    <string name="acidemia">Acidemia</string>
    <string name="alkalemia">Alkalemia</string>
    <string name="metabolicAcidosis">Metabolic Acidosis</string>
    <string name="additionalRespiratoryAlkalosis">Additional respiratory alkalosis</string>
    <string name="additionalRespiratoryAcidosis">Additional respiratory acidosis</string>
    <string name="albumin">Albumin</string>
    <string name="normalAnionGap">Normal anion gap</string>
    <string name="highAnionGap">High anion gap</string>
    <string name="urineNa">Urine Na</string>
    <string name="urineK">Urine K</string>
    <string name="urineCl">Urine Cl</string>
    <string name="rta">Renal tubular acidosis</string>
    <string name="urinaryAnionGapNegativeDDx">Diarrhea, Sodium infusion, Proximal RTA</string>
    <string name="highAnionGapDDx">Lactate, Keto acids, Toxic alcohols</string>
    <string name="respiratoryAcidosis">Respiratory acidosis</string>
    <string name="acuteRespiratoryAcidosis">Acute respiratory acidosis</string>
    <string name="additionalMetabolicAcidosis">Additional metabolic acidosis</string>
    <string name="chronicRespiratoryAcidosis">Chronic respiratory acidosis</string>
    <string name="additionalMetabolicAlkalosis">Additional metabolic alkalosis</string>
    <string name="age">Age</string>
    <string name="HypoventilationWithoutIntrinsicLungDisease">Hypoventilation without intrinsic lung disease</string>
    <string name="HypoventilationWithIntrinsicLungDiseaseVentilationPerfusionMismatchOrBoth">Hypoventilation with intrinsic lung disease, ventilation–perfusion mismatch, or both</string>
    <string name="acuteRespiratoryAlkalosis">Acute respiratory alkalosis</string>
    <string name="chronicRespiratoryAlkalosis">Chronic respiratory alkalosis</string>
    <string name="metabolicAlkalosis">Metabolic Alkalosis</string>
    <string name="respiratoryAlkalosis">Respiratory alkalosis</string>
    <string name="metabolicAlkalosisAndRespiratoryAcidosis">Metabolic alkalosis and respiratory acidosis</string>
    <string name="metabolicAcidosisAndRespiratoryAlkalosis">Metabolic acidosis and respiratory alkalosis</string>
    <string name="bloodGasAnalysisRef" translatable="false">Physiological Approach to Assessment of Acid–Base Disturbances\nN Engl J Med 2014;371:1434-45.</string>
    <string name="bloodGasAnalysisUrl" translatable="false">https://www.nejm.org/doi/full/10.1056/NEJMra1003327</string>
    <string name="acutePancreatitisBaseExcessTitle">Base Excess ≤ -3 mEq/L, or shock (systolic blood pressure ≤ 80 mmHg)</string>
    <string name="acutePancreatitisPaO2Title">PaO&lt;sub>2&lt;/sub> ≤ 60 mmHg, or respiratory failure (respirator needed)</string>
    <string name="acutePancreatitisBUNTitle">BUN ≥ 40 mg/dL (or Cr ≥ 2 mg/dL), or oliguria (urine volume ≤ 400 mL/ day even after hydration)</string>
    <string name="acutePancreatitisLDHTitle">LDH ≥ upper limit x 2</string>
    <string name="acutePancreatitisPltTitle">Platelet ≤ 100,000/ mm&lt;sup>3&lt;/sup></string>
    <string name="acutePancreatitisCaTitle">Total Ca ≤ 7.5 mg/dL</string>
    <string name="acutePancreatitisCRPTitle" translatable="false">CRP ≥ 15 mg/dL</string>
    <string name="acutePancreatitisSIRSTitle">3 or more of SIRS criteria apply</string>
    <string name="acutePancreatitisSIRSTitleNote">(1) Body temperature > 38°C or &lt; 36°C\n(2) Pulse > 90/ min\n(3) Respiratory rate > 20/min or paCO&lt;sub>2&lt;/sub> &lt; 32 toll\n(4) WBC > 12,000 or &lt; 4000/ mm&lt;sup>3&lt;/sup> or 10% blastcytes</string>
    <string name="acutePancreatitisAgeTitle">Age ≥ 70</string>
    <string name="acutePancreatitisCTTitle">Enhanced CT grade</string>
    <string name="severe">Severe&#xA0;</string>
    <string name="anteriorPararenalSpace">Anterior Pararenal space</string>
    <string name="rootOfMesocolon">Root of Mesocolon</string>
    <string name="beyondTheInferiorRootOfKidney">Beyond the inferior root of kidney</string>
    <string name="localizedToOneSegmentOrOnlyPeripancrease">Localized to one segment or only peripancrease</string>
    <string name="lessThanTwoSegments">Less than two segments</string>
    <string name="twoSengemtsOrMore">Two segements or more</string>
    <string name="acutePancreatitisCTGradeInflammationTitle">Extrapancreatic extension of inflammation</string>
    <string name="mild">Mild&#xA0;</string>
    <string name="acutePancreatitisCTGradePoorContrastTitleNote">Three segments (head, body, tail)</string>
    <string name="acutePancreatitis">Acute Pancreatitis</string>
    <string name="acutePancreatitisCTGradePoorContrastTitle">CE-CT grade: poor contrast region</string>
    <string name="netakiridoTitle">日常生活自立度&lt;small>（Japanese Only）&lt;/small></string>
    <string name="rankJ" translatable="false">生活自立\nランクJ</string>
    <string name="rankJNote" translatable="false">何らかの障害等を有するが、日常生活はほぼ自立しており独力で外出する\n1.　交通機関等を利用して外出する\n2.　隣近所へなら外出する</string>
    <string name="rankA" translatable="false">準寝たきり\nランクA</string>
    <string name="rankANote" translatable="false">屋内での生活は概ね自立しているが、介助なしには外出しない \n1.　介助により外出し、日中はほとんどベッドから離れて生活する \n2.　外出の頻度が少なく、日中も寝たり起きたりの生活をしている</string>
    <string name="rankBorC" translatable="false">寝たきり（ランクB/C）</string>
    <string name="rankBNote" translatable="false">ランクB\n屋内での生活は何らかの介助を要し、日中もベッド上での生活が主体であるが、座位を保つ</string>
    <string name="rankBNoteSubCategory" translatable="false">1. 車いすに移乗し、食事、排泄はベッドから離れて行う\n2. 介助により車いすに移乗する</string>
    <string name="rankCNote" translatable="false">ランクC\n1日中ベッド上で過ごし、排泄、食事、着替において介助を要する</string>
    <string name="rankCNoteSubCategory" translatable="false">1. 自力で寝返りをうつ\n2. 自力では寝返りもうてない </string>
    <string name="shougaiKoureisha" translatable="false">障害高齢者の日常生活自立度</string>
    <string name="ninchishoKoureisha" translatable="false">認知症高齢者の日常生活自立度</string>
    <string name="ninchiI" translatable="false">ランクI: 何らかの認知症を有するが、日常生活は家庭内及び社会的にほぼ自立している。</string>
    <string name="ninchiII" translatable="false">ランクII: 日常生活に支障を来たすような症状・行動や意思疎通の困難さが多少見られても、誰かが注意していれば自立できる。</string>
    <string name="ninchiIINote" translatable="false">IIa: 家庭外で上記Ⅱの状態がみられる。\nIIb: 家庭内でも上記Ⅱの状態が見られる。</string>
    <string name="ninchiIII" translatable="false">ランクIII\n日常生活に支障を来たすような症状・行動や意思疎通の困難さが見られ、介護を必要とする。 "</string>
    <string name="ninchiIIINote" translatable="false">IIIa: 日中を中心として上記Ⅲの状態が見られる。 IIIb: 夜間を中心として上記Ⅲの状態が見られる。</string>
    <string name="ninchiIV" translatable="false">"ランクIV: 日常生活に支障を来たすような症状・行動や意思疎通の困難さが頻繁に見られ、常に介護を必要とする。 "</string>
    <string name="ninchiV" translatable="false">"ランクV: 著しい精神症状や問題行動あるいは重篤な身体疾患が見られ、専門医療を必要とする。 "</string>
    <string name="netakiridoUrl" translatable="false">https://www.mhlw.go.jp/file/06-Seisakujouhou-12300000-Roukenkyoku/0000077382.pdf</string>
    <string name="netakiridoRefTitle" translatable="false">厚生労働省HP (PDF)</string>
    <string name="pancreaticTNMTitle">Pancreatic cancer TNM classification (8th)</string>
    <string name="T4" translatable="false">T4</string>
    <string name="N1" translatable="false">N1</string>
    <string name="N2" translatable="false">N2</string>
    <string name="M1" translatable="false">M1</string>
    <string name="esophagealTNMTitle">Esophageal Cancer TNM classification (8th)</string>
    <string name="N3" translatable="false">N3</string>
    <string name="TfactorTitleNoteEsophagealCancer">&lt;b>Tis&lt;/b>: high grade dysplasia\n&lt;b>T1a&lt;/b>: lamina propria or musclaris mucosase\n&lt;b>T1b&lt;/b>: submucosa\n&lt;b>T2&lt;/b>: muscularis propria\n&lt;b>T3&lt;/b>: adventitia\n&lt;b>T4a&lt;/b>: pleura, pericardium, azygos vein, diaphragm, or peritoneum\n&lt;b>T4b&lt;/b>: other adjacent structures, such as aorta, vertebral body, or trachea</string>
    <string name="NfactorTitleNoteEsophagealCancer">&lt;b>N1&lt;/b>: 1–2 regional lymph nodes\n&lt;b>N2&lt;/b>: 3–6\n&lt;b>N3&lt;/b>: 7 or more</string>
    <string name="MfactorTitleNoteEsophagealCancer">&lt;b>M1&lt;/b>: distant metastasis</string>
    <string name="mALBITitle" translatable="false">mALBI</string>
    <string name="mALBIRef" translatable="false">Liver cancer vol. 6,4 (2017): 325-336.</string>
    <string name="mALBIUrl" translatable="false">https://pubmed.ncbi.nlm.nih.gov/29234636/</string>
    <string name="totalBilirubin">Total bilirubin</string>
    <string name="mgdl" translatable="false">mg/dL</string>
    <string name="gdL" translatable="false">g/dL</string>
    <string name="num1" translatable="false">1</string>
    <string name="num2a" translatable="false">2a</string>
    <string name="num2b" translatable="false">2b</string>
    <string name="num3" translatable="false">3</string>
    <string name="umolL" translatable="false">μmol/L</string>
    <string name="gL" translatable="false">g/L</string>
    <string name="years">years</string>
    <string name="ast" translatable="false">AST</string>
    <string name="iul" translatable="false">IU/L</string>
    <string name="plateletCount">platelet count</string>
    <string name="unit109L" translatable="false"><![CDATA[10<sup>9</sup>/L]]></string>
    <string name="alt" translatable="false">ALT</string>
    <string name="liverFibrosisScoreSystemTitle">Liver Fibrosis Score System</string>
    <string name="lowRisk">Low Risk</string>
    <string name="intermediateRisk">Intermediate</string>
    <string name="highRisk">High Risk</string>
    <string name="fibrosisStage02">Fibrosis Stage 0-2</string>
    <string name="stage34">Stage 3-4</string>
    <string name="fib4score">FIB4 Score</string>
    <string name="apriScore">APRI score</string>
    <string name="fib4" translatable="false">FIB4</string>
    <string name="apri" translatable="false">APRI</string>
    <string name="astToPlateletRatioIndex" translatable="false">AST to Platelet Ratio Index (APRI)</string>
    <string name="shearWaveElastography" translatable="false">Shear Wave Elastography</string>
    <string name="ms" translatable="false">m/s</string>
    <string name="normal">Normal</string>
    <string name="compensatedAdvancedChronicLiverDisease">Compensated Advanced Chronic Liver Disease</string>
    <string name="cACLD" translatable="false">cACLD</string>
    <string name="apriUrl" translatable="false">https://pubmed.ncbi.nlm.nih.gov/30616027/</string>
    <string name="shearWaveElastographyUrl" translatable="false">https://doi.org/10.1148/radiol.2020192437</string>
    <string name="nafldFibrosisScore" translatable="false">NAFLD Fibrosis Score</string>
    <string name="nafldFibrosisScoreUrl" translatable="false">https://pubmed.ncbi.nlm.nih.gov/36727674/</string>
    <string name="bodyHeight">Body Height</string>
    <string name="cm" translatable="false">cm</string>
    <string name="bodyWeight">Body Weight</string>
    <string name="kg" translatable="false">Kg</string>
    <string name="dmPresence">Presence of IFG/diabetes</string>
    <string name="dmPresenceNote" translatable="false">Impaired Fasting Glucose or Diabetes Mellitus</string>
    <string name="unlikely">Unlikely</string>
    <string name="likely">Likely</string>
    <string name="elfScore">ELF score</string>
    <string name="fibrosisStage2">Fibrosis Stage2</string>
    <string name="fibrosisStage3">Fibrosis Stage3</string>
    <string name="f2" translatable="false">F2</string>
    <string name="f3" translatable="false">F3</string>
    <string name="elfScoreUrl" translatable="false">https://pubmed.ncbi.nlm.nih.gov/37088311/</string>
    <string name="hyaluronicAcid">Hyaluroninc Acid</string>
    <string name="ngml" translatable="false">ng/mL</string>
    <string name="timp1" translatable="false">TIMP-1</string>
    <string name="piiip" translatable="false">PIIIP</string>
    <string name="platelet">Platelet</string>
    <string name="diabetesMellitus">Diabetes Mellitus</string>
    <string name="fib4Url" translatable="false">https://pubmed.ncbi.nlm.nih.gov/36727674/</string>
    <string name="m2bpgi" translatable="false">M2BPGi</string>
    <string name="coi" translatable="false">COI</string>
    <string name="stage3">Stage 3</string>
    <string name="stage4">Stage 4</string>
    <string name="m2bpgiUrl" translatable="false">https://pubmed.ncbi.nlm.nih.gov/25326152/</string>
    <string name="bruntStaging">Brunt staging</string>
    <string name="nashCrnFibrosisStage02">NASH-CRN Fibrosis Stage 0-2</string>
    <string name="homairTitle" translatable="false">HOMA-IR</string>
    <string name="boaderline">Boarderline</string>
    <string name="insulinResistance">Insulin Resistance</string>
    <string name="fastingInsulin">Fasting Insulin</string>
    <string name="uUml" translatable="false">μU/mL</string>
    <string name="fastingGlucose">Fasting Glucose</string>
    <string name="mmoll" translatable="false">mmol/L</string>
    <string name="mmhg" translatable="false">mmHg</string>
    <string name="meql" translatable="false">mEq/L</string>
    <string name="acuteTonsillitisAlgorithmReference" translatable="false">気道感染症の抗菌薬適正使用に関する提言（日本感染症学会）</string>
    <string name="acuteTonsillitisAlgorithmReferenceUrl" translatable="false">https://www.kansensho.or.jp/uploads/files/guidelines/2211_teigen.pdf</string>
    <string name="T2a" translatable="false">T2a</string>
    <string name="T2b" translatable="false">T2b</string>
    <string name="TfactorTitleNoteLungCancer">
        &lt;b>Tis&lt;/b> Carcinoma in situ\n&lt;b>T1a&lt;/b> Tumor ≤ 1cm\n&lt;b>T1b&lt;/b> Tumor > 1cm but ≤ 2cm\n&lt;b>T1c&lt;/b> Tumor > 2 cm but ≤ 3cm\n&lt;b>T2a&lt;/b> Tumor > 3 cm but ≤ 4 cm, invades visceral pleura, invades an adjacent lobe, involves main bronchus (up to but not including the carina) or is associated with atelectasis or obstructive pneumonitis, extending to the hilar region, involving either part of or the entire lung\n&lt;b>T2b&lt;/b> Tumor > 4 cm but ≤ 5 cm\n&lt;b>T3&lt;/b> Tumor with any of the following features: tumor > 5 cm but 7 cm in greatest dimension. invades parietal pleura or chest wall. invades pericardium,phrenicnerve,or azygos vein. invades thoracic nerve roots (i.e.,T1,T2) or stellate ganglion separate tumor nodule(s) in the same lobe as the primary.\n&lt;b>T4&lt;/b> Tumor with any of the following features: tumor > 7 cm, invades mediastinum, thymus, trachea, carina, recurrent laryngeal nerve, vagus nerve, esophagus,or diaphragm invades heart, great vessels (aorta,superior or inferior vena cava, intrapericardial pulmonary arteries or veins), supra-aortic arteries, or brachiocephalic veins invades subclavian vessels, vertebral body, lamina, spinal canal, cervical nerve roots, or brachial plexus (i.e.,trunks, divisions, cords,or terminal nerves) separate tumor nodule(s) in a different ipsilateral lobe than that of the primary
    </string>
    <string name="NfactorTitleNoteLungCancer">
        &lt;b>N1&lt;/b> Metastasis in ipsilateral peribronchial or ipsilateral hilar or intrapulmonary lymph nodes, including involvement by direct extension\n&lt;b>N2&lt;/b> Metastasis in ipsilateral mediastinal or subcarinal lymph node(s)\n&lt;b>N2a&lt;/b> Metastasis(es) in a single ipsilateral mediastinal or in the subcarinal nodal station\n&lt;b>N2a&lt;/b> Metastases in multiple ipsilateral mediastinal nodal stations with or without involvement of the subcarinal nodal station\n&lt;b>N3&lt;/b> Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene or supraclavicular lymph node(s)
    </string>
    <string name="MfactorTitleNoteLungCancer">
        &lt;b>M1a&lt;/b> Tumor with pleural or pericardial nodules, or malignant pleural or pericardial effusions, separate tumor nodule(s) in a contralateral lobe\n&lt;b>M1b&lt;/b> Single extra thoracic metastasis in a single organ system\n&lt;b>M1c&lt;/b> Multiple extra thoracic metastases in a single or multiple organ system(s)
    </string>
    <string name="grade1" translatable="false">Grade 1</string>
    <string name="grade2a" translatable="false">Grade 2a</string>
    <string name="grade2b" translatable="false">Grade 2b</string>
    <string name="grade3" translatable="false">Grade 3</string>
    <string name="g2a" translatable="false">2a</string>
    <string name="g2b" translatable="false">2b</string>
    <string name="g3" translatable="false">3</string>
    <string name="lungTNMTitle">Lung Cancer TNM classification (9th)</string>
    <string name="hccTNMTitle">Hepatocellular Carcinoma TNM classification (8th)</string>
    <string name="TfactorTitleNoteHcc">&lt;b>T1&lt;/b> Solitary tumor ≤2 cm, or >2 cm without vascular invasion\n&lt;b>T1a&lt;/b> Solitary tumor ≤2 cm\n&lt;b>T1b&lt;/b> Solitary tumor >2 cm without vascular invasion\n&lt;b>T2&lt;/b> Solitary tumor >2 cm with vascular invasion, or multiple tumors, none >5 cm &lt;b>T3&lt;/b> Multiple tumors, at least one of which is >5 cm\n&lt;b>T4&lt;/b> Single tumor or multiple tumors of any size involving a major branch of the portal vein or hepatic vein, or tumor(s) with direct invasion of adjacent organs other than the gallbladder or with perforation of visceral peritoneum</string>
    <string name="NfactorTitleNoteHcc">N0 No regional lymph node metastasis N1 Regional lymph node metastasis</string>
    <string name="MfactorTitleNoteHcc">M0 No distant metastasis M1 Distant metastasis</string>
    <string name="intrahepaticCholangiocarcinomaTNMTitle">Intrahepatic Cholangiocarcinoma TNM Classificaiton (8th)</string>
    <string name="TfactorTitleNoteIntrahepaticCholangiocarcinoma">&lt;b>Tis&lt;/b> Carcinoma in Situ/n&lt;b>T1a&lt;/b> Solitary tumor ≤5 cm without vascular invasion\n&lt;b>T1b&lt;/b> Solitary tumor >5 cm without vascular invasion\n&lt;b>T2&lt;/b> Solitary tumor with vascular invasion, or multiple tumors with or without vascular invasion/n&lt;b>T3&lt;/b> Single tumor or multiple tumors with perforation of visceral peritoneum\n&lt;b>T4&lt;/b> Tumor(s) with direct invasion of nearby structures outside of the liver</string>
    <string name="NfactorTitleNoteIntrahepaticCholangiocarcinoma">N0 No regional lymph node metastasis N1 Regional lymph node metastasis</string>
    <string name="MfactorTitleNoteIntrahepaticCholangiocarcinoma">M0 No distant metastasis M1 Distant metastasis</string>
    <string name="prognosticFactor">Prognostic Factors</string>
    <string name="chads2AndHelte2s2Title" translatable="false">CHADS2/HELT-E&lt;sub>2&lt;/sub>S&lt;sub>2&lt;/sub> Score</string>
    <string name="congestiveHearFaiLureHistoryTitle">Congestive heart failure history</string>
    <string name="hepertensionHistoryTitle">Hypertension history</string>
    <string name="age75Title">Age ≥ 75</string>
    <string name="diabetesMellitusHistoryTitle">Diabetes mellitus history</string>
    <string name="strokeOrTIASymptomsPreviouslyTitle">Stroke or TIA symptoms previously</string>
    <string name="helte2s2" translatable="false">HELT-E&lt;sub>2&lt;/sub>S&lt;sub>2&lt;/sub></string>
    <string name="chads2Url" translatable="false">https://pubmed.ncbi.nlm.nih.gov/11401607/</string>
    <string name="strokeRateWithoutAnticoagulant">Stroke rate without anticoagulant</string>
    <string name="per100PatientYears" translatable="false">/100 patient-years</string>
    <string name="chads2" translatable="false">CHADS2</string>
    <string name="helte2s2Url" translatable="false">https://pubmed.ncbi.nlm.nih.gov/33762526/</string>
    <string name="elderly">Elderly, Age 75-84 years</string>
    <string name="lowBmi">Low BMI (&lt;18.5 kg/m<sup>2</sup>)</string>
    <string name="typeOfAf">Type of AF (persistent/permanent)</string>
    <string name="extremeElderly">Extreme Elderly, Age ≥ 85 years</string>
    <string name="previousStroke">Previous Stroke</string>
    <string name="perYear">/year</string>
    <string name="manegementAntithromboticsForEndoscopy">Management of antithrombotic agents for endoscopic procedures</string>
    <string name="antithromboticsUrl" translatable="false">https://pubmed.ncbi.nlm.nih.gov/34362780/</string>
    <string name="BsgAndESGE">BSG and ESGE</string>
    <string name="bCellDysfunction">β-cell dysfunction</string>
    <string name="homab" translatable="false">HOMA-β</string>
    <string name="present">Present</string>
    <string name="absent">Absent</string>
    <string name="homaIrHomaBetaTitle" translatable="false">HOMA-IR/HOMA-β</string>
    <string name="glasgowComaScaleTitle" translatable="false">Glasgow Coma Scale</string>
    <string name="openinresponsetopainappliedtothelimbsorsternum">Open in response to pain applied to the limbs or sternum</string>
    <string name="opentoverbalcommand">Open to verbal command</string>
    <string name="openspontaneously">Open spontaneously</string>
    <string name="eye">Eye opening</string>
    <string name="verbal">Verbal</string>
    <string name="incomprehensiblespeech">Incomprehensible speech</string>
    <string name="inappropriateanswerstoquestionswordsdiscernible">Inappropriate answers to questions; words discernible</string>
    <string name="disorientedbutabletoanswerquestions">Disoriented, but able to answer questions</string>
    <string name="oriented">Oriented</string>
    <string name="motor">Motor</string>
    <string name="respondstopainwithabnormalrigidextensiondecerebrateposture">Responds to pain with abnormal (rigid) extension (decerebrate posture)</string>
    <string name="respondstopainwithabnormalflexiondecorticateposture">Responds to pain with abnormal flexion (decorticate posture)</string>
    <string name="withdrawsfrompainstimuli">Withdraws from pain stimuli</string>
    <string name="respondstopainwithpurposefulmovement">Responds to pain with purposeful movement</string>
    <string name="obeyscommands">Obeys commands</string>
    <string name="caIndex">CA index</string>
    <string name="caIndexUrl">https://pubmed.ncbi.nlm.nih.gov/31538241/</string>
    <string name="type4collagen7S">Type IV collagen 7S</string>
    <string name="fibrosisStage1">Fibrosis (stage ≥ 1)</string>
    <string name="disorderOfSerumSodium">Disorder of serum sodium</string>
    <string name="disorderOfSerumSodiumReference">Hyponatremia</string>
    <string name="disorderOfSerumSodiumReferenceUrl" translatable="false">https://pubmed.ncbi.nlm.nih.gov/24569125/</string>
    <string name="sodium">Na&lt;sup>+&lt;/sup></string>
    <string name="hyponatremia">Hyponatremia</string>
    <string name="normonatremia">Normonatremia</string>
    <string name="hypernatremia">Hypernatremia</string>
    <string name="mOsmKg" translatable="false">mOsm/kg</string>
    <string name="serumOsmolality">Serum osmolality</string>
    <string name="lowOsmolality">Low osmolality</string>
    <string name="IsotonicHyponatraemia">Isotonic hyponatraemia</string>
    <string name="highOsmolality">High osmolality</string>
    <string name="HyperglycemiaMannitolAndGlycinByIrrigationFluids">Hyperglycemia due to uncontrolled diabetes mellitus, mannitol and glycin by irrigation fluids</string>
    <string name="serumGlucose">Serum glucose</string>
    <string name="hypertonicHyponatremia">Hypertonic hyponatremia</string>
    <string name="HyperglycemiaMayBePresent">Hyperglycemia may be present</string>
    <string name="hypotonicHyponatremia">Hypotonic hyponatremia</string>
    <string name="acuteOrSevereSymptoms">Acute or severe symptoms?</string>
    <string name="considerImmediateTreatmentWithHypertonicSaline">Consider immediate treatment with hypertonic saline</string>
    <string name="urineOsmolality">Urine Osmolarity</string>
    <string name="primaryPolydipsia">Primary polydipsia</string>
    <string name="lowSoluteIntake">Low solute intake</string>
    <string name="beerPotomania" translatable="false">Beer potomania</string>
    <string name="urineSodiumConcentration">Urine sodium concentration</string>
    <string name="lowEffectiveArterialBloodVolume">Low effective arterial blood volume</string>
    <string name="ifEcfExpadedConsider">If ECF expaded consider</string>
    <string name="hearFailure">Heart failure</string>
    <string name="liverCirrhosis">Liver cirrhosis</string>
    <string name="nephroticSyndrome">Nephrotic syndrome</string>
    <string name="ifEcfReducedConsider">If ECF reduced consider</string>
    <string name="diarrheaAndVomiting">Diarrhea and vomiting</string>
    <string name="thirdSpacing">Third spacing</string>
    <string name="remoteDiuretics">Remote Diuretics</string>
    <string name="diureticsOrKidneyDisease">Diuretics or kidney disease?</string>
    <string name="consider">Consider</string>
    <string name="diuretics">Diuretics</string>
    <string name="kidneyDisease">Kidney disease</string>
    <string name="allOtherCauses">All other causes</string>
    <string name="vomiting">Vomiting</string>
    <string name="primaryAdrenalInsufficiency">Primary adrena insufficiency</string>
    <string name="renalSaltWasting" translatable="false">Renal salt wasting</string>
    <string name="cerebralSaltWasting" translatable="false">Cerebral salt wasting</string>
    <string name="occultDiuretics">Occult diuretics</string>
    <string name="ifEcfNormalConsider">If ECF normal consider</string>
    <string name="siad">SIAD</string>
    <string name="secondaryAdrenalInsufficiency">Secondary adrenal insufficiency</string>
    <string name="hypothyroidism">Hypothyroidism</string>
    <string name="sodiumDifferentialDiagnosisTitle">Hyponatremia algorithm</string>
    <string name="lung">Lung</string>
    <string name="pneumonia">Pneumonia</string>
    <string name="liver">Liver</string>
    <string name="af">AF</string>
    <string name="stroke">Stroke</string>
    <string name="search">Search</string>
    <string name="lilleModel" translatable="false">Lille model</string>
    <string name="lilleModelUrl" translatable="false">https://pubmed.ncbi.nlm.nih.gov/17518367/</string>
    <string name="bilirubinDay0">Bilirubin day 0</string>
    <string name="bilirubinDay7">Bilirubin day 7</string>
    <string name="creatinine">Creatinine</string>
    <string name="ptInr" translatable="false">PT-INR</string>
    <string name="lilleModelInr">Lille model-INR</string>
    <string name="alcoholicHepatitis">Alcoholic Hepatitis</string>
    <string name="ecog" translatable="false">ECOG</string>
    <string name="ecogPerformanceStatus" translatable="false">ECOG Performance status</string>
    <string name="ecogUrl" translatable="false">https://jcog.jp/assets/ctcv20_4-30-992.pdf</string>
    <string name="ecog0">Fully active, able to carry on all pre-disease performance without restriction.</string>
    <string name="ecog1">Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light housework, office work.</string>
    <string name="ecog2">Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours.</string>
    <string name="ecog3">Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours.</string>
    <string name="ecog4">Completely disabled. Cannot carry on any selfcare.  Totally confined to bed or chair.</string>
    <string name="EcogEasternCooperativeOncologyGroup" translatable="false">ECOG（Eastern Cooperative Oncology Group）</string>
    <string name="Ps" translatable="false">PS</string>
    <string name="infusionCalculator">Infusion calculator</string>
    <string name="ugkgmin" translatable="false">μg/kg/min</string>
    <string name="mlhr" translatable="false">mL/hr</string>
    <string name="totalVolume">Total volume</string>
    <string name="flowRate">Flow rate</string>
    <string name="ml" translatable="false">mL</string>
    <string name="saline">saline</string>
    <string name="Drug">Drug</string>
    <string name="mg" translatable="false">mg</string>
    <string name="targetDosageOfDrug">Target dosage of drug</string>
    <string name="totalDrugDose">Total drug dose</string>
    <string name="findDrugDosage">Find drug dosage</string>
    <string name="findFlowRate">Find flow rate</string>
    <string name="ikashiRinryokuMasterKensaku">医科診療行為マスター検索（Japanese Only）</string>
    <string name="IkaShinryokoiMaster">医科診療行為マスター</string>
    <string name="IkaShinryokoiMasterUrl" translatable="false">https://shinryohoshu.mhlw.go.jp/shinryohoshu/downloadMenu/</string>
    <string name="icd10" translatable="false">ICD-10</string>
    <string name="icd10Url" translatable="false">https://www.cdc.gov/nchs/icd/icd-10-cm/files.html</string>
    <string name="icd10JapaneseUrl" translatable="false">https://www2.medis.or.jp/stdcd/byomei/download2019.html</string>
    <string name="icd10japanese" translatable="false">ICD-10（日本語）</string>
    <string name="wilsonTitle">Wilson’s disease scoring system</string>
    <string name="normal02" translatable="false"><![CDATA[Normal (>0.2 g/L)]]></string>
    <string name="between0102" translatable="false">0.1-0.2 g/L</string>
    <string name="below01" translatable="false"><![CDATA[<0.1 g/L]]></string>
    <string name="above4" translatable="false"><![CDATA[>5×ULN (>4 μmol/g)]]></string>
    <string name="between084" translatable="false">0.8-4 μmol/g</string>
    <string name="normal08" translatable="false"><![CDATA[Normal (<0.8 μmol/g)]]></string>
    <string name="rhodaninePositiveGranules">Rhodanine-positive granules</string>
    <string name="between12">1-2× ULN</string>
    <string name="above2"><![CDATA[>2× ULN]]></string>
    <string name="above5"><![CDATA[Normal, but >5× ULN after D-penicillamine]]></string>
    <string name="bothChromosomes">On both chromosomes detected</string>
    <string name="oneChromosome">On 1 chromosome detected</string>
    <string name="noMutation">No mutations detected</string>
    <string name="KFrings">Kayser–Fleischer rings</string>
    <string name="neurologicSymptoms">Neurologic symptoms</string>
    <string name="serumCeruloplasmin">Serum ceruloplasmin</string>
    <string name="coombsNegativeHymolyticAnemia">Coombs-negative hemolytic anemia</string>
    <string name="liverCopper">Liver copper (in the absence of cholestasis)</string>
    <string name="urinaryCopper">Urinary copper (in the absence of acute hepatitis)</string>
    <string name="mutationAnalysis">Mutation analysis</string>
    <string name="atp7bMutation">ATP7B mutation</string>
    <string name="urinaryCopperNote" translatable="false">1.6 μmol/24h (100 μg/24h)</string>
    <string name="liverCopperNote" translatable="false">>250 μg/g dry weight (2), 50–250 μg/g (1), &lt;50 μg/g (0). Rhodamine can be selected if no quantitative liver copper available</string>
    <string name="wilsonUrl" translatable="false">https://pubmed.ncbi.nlm.nih.gov/22340672/</string>
    <string name="wilsonRefTitle" translatable="false">EASL Clinical Practice Guidelines: Wilson\'s disease</string>
    <string name="neurologicSymptomsNote">Motor abnormalities with Parkinsonian characteristics of dystonia, hypertonia and rigidity, choreic or pseudosclerotic, with tremors and dysarthria</string>
    <string name="kayserFleischerRingsNote">in Desçemet’s membrane of the cornea</string>
    <string name="established">established</string>
    <string name="possible">possible</string>
    <string name="veryUnlikely">very unlikely</string>
    <string name="lilleModelHelp">A model for predicting survival at 6 months in patients with alcoholic hepatitis being treated with prednisolone</string>
    <string name="ok">OK</string>
    <string name="Curb65AdropTitle">CURB-65/A-Drop</string>
    <string name="Curb65">CURB-65</string>
    <string name="Curb65Url">https://pubmed.ncbi.nlm.nih.gov/12728155/</string>
    <string name="aDrop">A-drop</string>
    <string name="curb65">CURB-65</string>
    <string name="crb65">CRB-65</string>
    <string name="urea7mmol"><![CDATA[Urea > 7 mmol/L (19.6 mg/dL)]]></string>
    <string name="respirationRate30">Respiratory rate ≧ 30/min</string>
    <string name="bloodPressure9060"><![CDATA[Blood pressure (SBP < 90 mmHg or DBP ≦ 60 mmHg)]]></string>
    <string name="age65">Age ≧ 65 years</string>
    <string name="curb65LiteralScoreLow">Mortality low (1.5%)</string>
    <string name="curb65LiteralScoreIntermediage">Mortality intermediate (9.2%)</string>
    <string name="curb65LiteralScoreHigh">Mortality high (22%)</string>
    <string name="error">Error</string>
    <string name="crb65LiteralScoreLow">Mortality low (1.2%)</string>
    <string name="crb65LiteralScoreIntermediage">Mortality intermediate (8.15%)</string>
    <string name="crb65LiteralScoreHigh">Mortality high (31%)</string>
    <string name="curb65aDrophelp">Assessment of severity in community acquired pneumonia</string>
    <string name="curb65AdropTitle">CURB-65/ A-drop</string>
    <string name="about">About</string>
    <string name="reference">Reference</string>
    <string name="unknown">Unknown</string>
    <string name="notAssessed">NA</string>
    <string name="ureaNitrogen">Urea Nitrogen</string>
    <string name="systolicBloodPressure">Systolic Blood Pressure</string>
    <string name="diastolicBloodPressure">Diastoic Blood Pressure</string>
    <string name="male">Male</string>
    <string name="female">Female</string>
    <string name="gender">Gender</string>
    <string name="Adrop">A-drop (Japanese)</string>
    <string name="AdropUrl">https://www.jrs.or.jp/publication/file/adult_pneumonia1-3.pdf</string>
    <string name="shikashiRinryokuMasterKensaku" translatable="false">歯科診療行為マスター検索</string>
    <string name="ShikaShinryokoiMaster" translatable="false">歯科診療行為マスター</string>
    <string name="ShikaShinryokoiMasterUrl">https://shinryohoshu.mhlw.go.jp/shinryohoshu/downloadMenu/</string>
    <string name="aldreteTitle">Modified Aldrete Score</string>
    <string name="aldreteRefTitle">J Clin Anesth. 1995 Feb;7(1):89-91.</string>
    <string name="aldreteUrl">https://pubmed.ncbi.nlm.nih.gov/7772368/</string>
    <string name="acceptableForDischarge">Acceptable for discharge</string>
    <string name="closeObservation">Indications for continuous close observation</string>
    <string name="fourExtremities">Able to move 4 extremities voluntarily or on command</string>
    <string name="twoExtremities">Able to move 2 extremities voluntarily or on command</string>
    <string name="noExtremities">Unable to move extremities voluntarily or on command</string>
    <string name="breatheDeeply">Able to breathe deeply and cough freely</string>
    <string name="dyspneaOrLimited">Dyspnea or limited breathing</string>
    <string name="apneic">Apneic</string>
    <string name="twentyPercent">BP ± 20% of pre-anesthetic level</string>
    <string name="fortyninePercent">BP ± 20% to 49% of pre-anesthetic level</string>
    <string name="fiftyPercent">BP ± 50% of pre-anesthetic level</string>
    <string name="fullyAwake">Fully awake</string>
    <string name="arousableOnCalling">Arousable on calling</string>
    <string name="noResponding">No responding</string>
    <string name="roomAir">Able to maintain O&lt;sub>2&lt;/sub> saturation >92% on room air</string>
    <string name="aboveNinety">Needs O&lt;sub>2&lt;/sub> inhalation to maintain O&lt;sub>2&lt;/sub> saturation >90%</string>
    <string name="belowNinety">O&lt;sub>2&lt;/sub> saturation &lt;90% even with O&lt;sub>2&lt;/sub> supplement</string>
    <string name="acitivity">Activity</string>
    <string name="respiration">Respiration</string>
    <string name="circulation">Circulation</string>
    <string name="cousciousness">Consciousness</string>
    <string name="o2saturation">O&lt;sub>2&lt;/sub> saturation</string>
    <string name="modifiedAldreteScore">Modified Aldrete Score</string>
    <string name="aldrete">Aldrete</string>
    <string name="pacu">Post-anesthesia scoring system used in the Post-Anesthesia Care Unit</string>
    <string name="twentyTofortynine" translatable="false">± 20% to 49%</string>
    <string name="plusTwentyTofortynine" translatable="false">+20–49%:</string>
    <string name="minusTwentyTofortynine" translatable="false">-20–49%:</string>
    <string name="gastricTNMTitle">Gastric cancer TNM classification</string>
    <string name="N3a" translatable="false">N3a</string>
    <string name="N3b" translatable="false">N3b</string>
    <string name="TfactorTitleNoteGastricCancer">&lt;b>Tis&lt;/b> Carcinoma in situ: intraepithelial tumor without invasion of the lamina propria; high grade dysplasia\n&lt;b>T1&lt;/b> Tumor invades the lamina propria, muscularis mucosae or submucosa\n&lt;b>T1a&lt;/b> Tumor invades the lamina propria or muscularis mucosae\n&lt;b>T1b&lt;/b> Tumor invades the submucosa\n&lt;b>T2&lt;/b> Tumor invades the muscularis propria\n&lt;b>T3&lt;/b> Tumor penetrates the subserosal connective tissue without invasion of the visceral peritoneum or adjacent structures\n&lt;b>T4&lt;/b> Tumor invades the serosa (visceral peritoneum) or adjacent structures\n&lt;b>T4a&lt;/b> Tumor invades the serosa (visceral peritoneum)\n&lt;b>T4b&lt;/b> Tumor invades adjacent structures/organs</string>
    <string name="NfactorTitleNoteGastricCancer">&lt;b>N1&lt;/b> Metastasis in one or two regional lymph nodes\n&lt;b>N2&lt;/b> Metastasis in three to six regional lymph nodes\n&lt;b>N3&lt;/b> Metastasis in seven or more regional lymph nodes\n&lt;b>N3a&lt;/b> Metastasis in seven to 15 regional lymph nodes\n&lt;b>T3b&lt;/b> Metastasis in 16 or more regional lymph nodes</string>
    <string name="MfactorTitleNoteGastricCancer">&lt;b>M0&lt;/b> No distant metastasis\n&lt;b>M1&lt;/b> Distant metastasis</string>
    <string name="gastrangercancerTNMTitle">Gastric Cancer TNM classification (8th)</string>
    <string name="ckdGuideline">KDIGO 2024 Guideline for CKD</string>
    <string name="ckdGuidelineUrl" translatable="false">https://www.kidney-international.org/article/S0085-2538(23)00766-4/fulltext</string>
    <string name="ckdGuidelineTitle">Prognosis of CKD by GFR and albuminuria categories</string>
    <string name="urineAlbumin">Urine Albumin</string>
    <string name="urineCreatinine">Urine Creatinine</string>
    <string name="urineAlbuminCreatinineRatio">Urine Albumin Creatinine Ratio</string>
    <string name="mgg" translatable="false">mg/g</string>
    <string name="mgmmol" translatable="false">mg/mmol</string>
    <string name="urineTotalProtein">Urine Total Protein</string>
    <string name="urineTotalProteinCreatinineRatio">Urine Total Protein Creatinine Ratio</string>
    <string name="gfr">GFR</string>
    <string name="mlmin173m2"><![CDATA[ml/min/1.73m<sup>2</sup>]]></string>
    <string name="moderatelyIncreasedRisk">Moderately increased risk</string>
    <string name="veryHighRisk">Very high risk</string>
    <string name="kidney">Kidney</string>
    <string name="chronic">Chronic</string>
    <string name="gg" translatable="false">g/g</string>
    <string name="mmolL" translatable="false">mmol/L</string>
    <string name="g3a" translatable="false">G3a</string>
    <string name="g3b" translatable="false">G3b</string>
    <string name="g4" translatable="false">G4</string>
    <string name="g5" translatable="false">G5</string>
    <string name="g1" translatable="false">G1</string>
    <string name="g2" translatable="false">G2</string>
    <string name="a1" translatable="false">A1</string>
    <string name="a2" translatable="false">A2</string>
    <string name="a3" translatable="false">A3</string>
    <string name="persistentAlbuminuriaCategories">Persistent albuminuria categories</string>
    <string name="persistentProteinuriaCategories">Persistent Proteinuria Categories</string>
    <string name="gfrCategories">GFR categories</string>
    <string name="dateTitle">Days calculation</string>
    <string name="year">Year</string>
    <string name="month">Month</string>
    <string name="day">Day</string>
    <string name="todayStartingDate">Today (starting day)</string>
    <string name="yearMonthDay">Year/Month/Day</string>
    <string name="endDate">End date</string>
    <string name="numberOfDays">Number of Days</string>
    <string name="days">days</string>
    <string name="sleTitle">Classification criteria for SLE</string>
    <string name="sleRefTitle" translatable="false">2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus</string>
    <string name="sleUrl" translatable="false">https://pubmed.ncbi.nlm.nih.gov/31385462/</string>
    <string name="classifyAsSle">Classify as Systemic Lupus Erythematosus</string>
    <string name="doNotMeetTheCriteria">Do not meet the criteria</string>
    <string name="eightyOrMore" translatable="false">≧ 1: 80</string>
    <string name="lessThanEighty"><![CDATA[< 1: 80]]></string>
    <string name="slesEntryCriterion">Antinuclear antibodies (ANA) at a titer</string>
    <string name="slesEntryCriterionNote">HEp-2 cells or an equivalent positive test (ever)</string>
    <string name="constitutional">Constitutional</string>
    <string name="fever">Fever</string>
    <string name="leukopenia">Leukopenia</string>
    <string name="thrombocytopenia">Thrombocytopenia</string>
    <string name="autoimmuneHemolysis">Autoimmune hemolysis</string>
    <string name="delirium">Delirium</string>
    <string name="psychosis">Psychosis</string>
    <string name="seizure">Seizure</string>
    <string name="nonScarringAlopecia">Non-scarring alopecia</string>
    <string name="oralUlcers">Oral ulcers</string>
    <string name="subacuteCutaneousOrDscoidLupus">Subacute cutaneous OR discoid lupus</string>
    <string name="acuteCutaneousLupus">Acute cutaneous lupus</string>
    <string name="pleuralOrPericardialEffusion">Pleural or pericardial effusion</string>
    <string name="acutePericarditis">Acute pericarditis</string>
    <string name="jointInvolvement">Joint involvement</string>
    <string name="proteinuria"><![CDATA[Proteinuria > 0.5 g/24h]]></string>
    <string name="renalBiopsyClassIIorV">Renal biopsy Class II or V lupus nephritis</string>
    <string name="renalBiopsyClassIIIorIV">Renal biopsy Class III or IV lupus nephritis</string>
    <string name="antiphospholipidAntibodies">Anti-cardiolipin antibodies OR Anti-β2GP1 antibodies OR Lupus anticoagulant</string>
    <string name="lowC3OrC4">Low C3 OR low C4</string>
    <string name="lowC3AndC4">Low C3 AND low C4</string>
    <string name="sleSpecificAntibodies">Anti-dsDNA antibody OR Anti-Smith antibody</string>
    <string name="hematologic">Hematologic</string>
    <string name="neuropsychiatric">Neuropsychiatric</string>
    <string name="mucocutaneous">Mucocutaneous</string>
    <string name="serosal">Serosal</string>
    <string name="musculoskeletal">Musculoskeletal</string>
    <string name="renal">Renal</string>
    <string name="antiphospholipid">Antiphospholipid antibodies</string>
    <string name="complement">Complement proteins</string>
    <string name="additiveCriteria">Additive criteria</string>
    <string name="secondCommentSle">Do not count a criterion if there is a more likely explanation than SLE.\nOccurrence of a criterion on at least one occasion is sufficient.\nSLE classification requires at least one clinical criterion and ≥10 points.\nCriteria need not occur simultaneously.\nWithin each domain, only the highest weighted criterion is counted toward the total score</string>
    <string name="antiphospholipidNote">Anti-β2GPI = anti–β2-glycoprotein I\n&lt;b>Positive antiphospholipid antibodies&lt;/b>
    Anticardiolipin antibodies (IgA, IgG, or IgM) at medium or high titer (>40 APL, GPL, or MPL, or >the 99th percentile) or positive anti-β2GPI antibodies (IgA, IgG, or IgM) or positive lupus anticoagulant
    </string>
    <string name="hematologicNote">WBC &lt; 4,000/mm&lt;sup>3&lt;/sup>, Plt &lt; 100,000/mm&lt;sup>3&lt;/sup&lt;\n&lt;b>Autoimmune hemolysis&lt;/b> Evidence of hemolysis, such as reticulocytosis, low haptoglobin, elevated indirect bilirubin, elevated LDH, AND positive Coombs’ (direct antiglobulin) test</string>
    <string name="slesJapRefTitle" translatable="false">全身性エリテマトーデス（SLE）（指定難病４９）(Japanese)</string>
    <string name="sleJapsUrl" translatable="false">https://www.nanbyou.or.jp/entry/215</string>
    <string name="constitutionalNote"><![CDATA[Temperature >38.3°C]]></string>
    <string name="neuropsychiatricNote">&lt;b>Delirium&lt;/b> Characterized by 1) change in consciousness or level of arousal with reduced ability to focus, 2) symptom development over hours to &lt;2 days, 3) symptom fluctuation throughout the day, 4) either 4a) acute/subacute change in cognition (e.g., memory deficit or disorientation), or 4b) change in behavior, mood, or affect (e.g., restlessness, reversal of sleep/wake cycle)\n&lt;b>Psychosis&lt;/b> Characterized by 1) delusions and/or hallucinations without insight and 2) absence of delirium\n&lt;b>Seizure&lt;/b> Primary generalized seizure or partial/focal seizure</string>
    <string name="mucocutaneousNote">
    &lt;b>Non-scarring alopecia&lt;/b>
    Non-scarring alopecia observed by a clinician\n&lt;b>Oral ulcers&lt;/b>
        Oral ulcers observed by a clinician\n&lt;b>Subacute cutaneous OR discoid lupus&lt;/b>
        &lt;i>Subacute cutaneous lupus erythematosus observed by a clinician:&lt;/i>
    Annular or papulosquamous (psoriasiform) cutaneous eruption, usually photodistributed If skin biopsy is performed, typical changes must be present (interface vacuolar dermatitis consisting of a perivascular lymphohistiocytic infiltrate, often with dermal mucin noted).
    \nOR\n&lt;i>Discoid lupus erythematosus observed by a clinician:&lt;/i> <!-- THIS LINE NOW USES &lt;i> to be consistent -->
        Erythematous-violaceous cutaneous lesions with secondary changes of atrophic scarring, dyspigmentation, often follicular hyperkeratosis/plugging (scalp), leading to scarring alopecia on the scalp If skin biopsy is performed, typical changes must be present (interface vacuolar dermatitis consisting of a perivascular and/or periappendageal lymphohistiocytic infiltrate. In the scalp, follicular keratin plugs may be seen. In longstanding lesions, mucin deposition may be noted)\n&lt;b>Acute cutaneous lupus&lt;/b>
    Malar rash or generalized maculopapular rash observed by a clinician† If skin biopsy is performed, typical changes must be present (interface vacuolar dermatitis consisting of a perivascular lymphohistiocytic infiltrate, often with dermal mucin noted. Perivascular neutrophilic infiltrate may be present early in the course)
</string>
    <string name="serosalNote">&lt;b>Pleural or pericardial effusion&lt;/b>
        Imaging evidence (such as ultrasound, x-ray, CT scan, MRI) of pleural or pericardial effusion, or both\n&lt;b>Acute pericarditis&lt;/b>
        ≥2 of 1) pericardial chest pain (typically sharp, worse with inspiration, improved by leaning forward), 2) pericardial rub, 3) EKG with new widespread ST elevation or PR depression, 4) new or worsened pericardial effusion on imaging (such as ultrasound, x-ray, CT scan, MRI)</string>
    <string name="renalNote">&lt;b>Proteinuria&lt;/b>
        >0.5 g/24 hours Proteinuria >0.5 g/24 hours by 24-hour urine or equivalent spot urine protein-tocreatinine ratio\n&lt;b>Class II or V lupus nephritis on renal biopsy according to ISN/RPS 2003 classification&lt;/b>\n&lt;i>Class II:&lt;/i>
        Mesangial proliferative lupus nephritis: purely mesangial hypercellularity of any degree or mesangial matrix expansion by light microscopy, with mesangial immune deposit. A few isolated subepithelial or subendothelial deposits may be visible by immunofluorescence or electron microscopy, but not by light microscopy\n&lt;i>Class V:&lt;/i>
        Membranous lupus nephritis: global or segmental subepithelial immune deposits or their morphologic sequelae by light microscopy and by immunofluorescence or electron microscopy, with or without mesangial alterations\n&lt;b>Class III or IV lupus nephritis on renal biopsy according to ISN/RPS 2003 classification&lt;/b>
        &lt;i>Class III:&lt;/i>
        Focal lupus nephritis: active or inactive focal, segmental, or global endocapillary or extracapillary glomerulonephritis involving &lt;50% of all glomeruli, typically with focal subendothelial immune deposits, with or without mesangial alterations&lt;i>Class IV:&lt;/i>
        Diffuse lupus nephritis: active or inactive diffuse, segmental, or global endocapillary or extracapillary glomerulonephritis involving ≥50% of all glomeruli, typically with diffuse subendothelial immune deposits, with or without mesangial alterations. This class includes cases with diffuse wire loop deposits but with little or no glomerular proliferation
    </string>
    <string name="complementNote">&lt;b>Low C3 OR low&lt;/b> C4 C3 OR C4 below the lower limit of normal\n&lt;b>Low C3 AND low C4&lt;/b> Both C3 AND C4 below their lower limits of normal</string>
    <string name="sleSpecificAntibodiesNote">&lt;b>Anti-dsDNA antibodies OR anti-Sm antibodies&lt;/b> Anti-dsDNA antibodies in an immunoassay with demonstrated ≥90% specificity for SLE against relevant disease controls OR anti-Sm antibodies</string>
    <string name="systemicLupusErythemothosus">Systemic Lupus Erythematosus</string>
    <string name="classifyAsRa">Classify as RA</string>
    <string name="raTitle">Classification criteria for Rheumatoid Arthritis</string>
    <string name="raRefTitle">The 2010 American College of Rheumatology/European League Against Rheumatism classifi cation criteria for RA</string>
    <string name="raUrl" translatable="false">https://pubmed.ncbi.nlm.nih.gov/20699241/</string>
    <string name="atLeastOneJoint">" have at least 1 joint with defi nite clinical synovitis (swelling)"</string>
    <string name="noBetterExplained">with the synovitis not better explained by another disease</string>
    <string name="oneLargeJoint">1 large joint</string>
    <string name="twoToTenLargeJoints">2−10 large joints</string>
    <string name="oneToThreeSmallJoints">1−3 small joints (with or without involvement of large joints)</string>
    <string name="fourOrTenSmallJoints">4−10 small joints (with or without involvement of large joints)</string>
    <string name="moreThanTenJoints"><![CDATA[>10 joints (at least 1 small joint)]]></string>
    <string name="negativeRfAndNegativeAcpa">Negative RF and negative ACPA</string>
    <string name="lowPositiveRfAndLowPositiveAcpa">Low-positive RF or low-positive ACPA</string>
    <string name="highPositiveRfOrHighPositiveAcpa">High-positive RF or high-positive ACPA</string>
    <string name="normalCrpAndNormalEsr">Normal CRP and normal ESR</string>
    <string name="abnormlaCrpOrNormalEsr">Abnormal CRP or abnormal ESR</string>
    <string name="lessThanSixWeeks"><![CDATA[<6 weeks]]></string>
    <string name="sixWeeksOrMore">≥6 weeks</string>
    <string name="lowPositiveRfOrLowPositiveAcpa">Low-positive RF or low-positive ACPA</string>
    <string name="raEntryCriterion">Target population (Who should be tested?): Patients who</string>
    <string name="raEntryCriterionNote">&lt;b>*&lt;/b> The criteria are aimed at classification of newly presenting patients. In addition, patients with erosive disease typical of rheumatoid arthritis (RA) with a history compatible with prior fulfilment of the 2010 criteria should be classified as having RA. Patients with long-standing disease, including those whose disease is inactive (with or without treatment) who, based on retrospectively available data, have previously fulfilled the 2010 criteria should be classified as having RA.\n&lt;b>†&lt;/b> Differential diagnoses differ in patients with different presentations, but may include conditions such as systemic lupus erythematosus, psoriatic arthritis and gout. If it is unclear about the relevant differential diagnoses to consider, an expert rheumatologist should be consulted.</string>
    <string name="jointInvolvementRa">Joint involvement</string>
    <string name="jointInvolvementNote">&lt;b>§&lt;/b> Joint involvement refers to any swollen or tender joint on examination, which may be confirmed by imaging evidence of synovitis. Distal interphalangeal joints, first carpometacarpal joints and first metatarsophalangeal joints are excluded from assessment. Categories of joint distribution are classified according to the location and number of involved joints, with placement into the highest category possible based on the pattern of joint involvement.\n¶’Large joints’ refers to shoulders, elbows, hips, knees and ankles.\n&lt;b>**&lt;/b> ’Small joints’ refers to the metacarpophalangeal joints, proximal interphalangeal joints, second to fifth metatarsophalangeal joints, thumb interphalangeal joints and wrists.\n&lt;b>††&lt;/b>In this category, at least one of the involved joints must be a small joint; the other joints can include any combination of large and additional small joints, as well as other joints not specifically listed elsewhere (eg, temporomandibular, acromioclavicular, sternoclavicular, etc.). </string>
    <string name="serology">Serology (at least 1 test result is needed for classification)</string>
    <string name="serologyNote">&lt;b>ACPA&lt;/b> anti-citrullinated protein antibody.\n&lt;b>††&lt;/b> In this category, at least one of the involved joints must be a small joint; the other joints can include any combination of large and additional small joints, as well as other joints not specifically listed elsewhere (eg, temporomandibular, acromioclavicular, sternoclavicular, etc.).</string>
    <string name="acutePhaseReactants">Acute-phase reactants (at least 1 test result is needed for classifi cation)</string>
    <string name="nacutePhaseReactantsNote">&lt;b>§§&lt;/b>Normal/abnormal is determined by local laboratory standards.</string>
    <string name="durationOfSymptoms">Duration of symptoms</string>
    <string name="durationOfSymptomsNote">&lt;b>¶¶&lt;/b>Duration of symptoms refers to patient self-report of the duration of signs or symptoms of synovitis (eg, pain, swelling, tenderness) of joints that are clinically involved at the time of assessment, regardless of treatment status.</string>
    <string name="rheumatoidArthritis">Reumatoid Arthritis</string>
    <string name="jgCalendarUrl" translatable="false">https://en.wikipedia.org/wiki/Japanese_era_name</string>
    <string name="jEraName" translatable="false">Japanese Era Name</string>
    <string name="JgCalendarTitle">Japanese-Gregorian calendar conversion</string>
    <string name="ad">A.D.</string>
    <string name="meji">Meiji</string>
    <string name="taisho">Taisho</string>
    <string name="showa">Showa</string>
    <string name="heisei">Heisei</string>
    <string name="reiwa">Reiwa</string>
    <string name="nen">" "</string>
    <string name="meiji">Meiji</string>
    <string name="westernCalendar">Western calendar</string>
    <string name="japaneseCalendar">Japanese calendar</string>
    <string name="calendar">Calendar</string>
    <string name="sepsis3" translatable="false">The Third International Consensus Definitions  for Sepsis and Septic Shock (Sepsis-3)</string>
    <string name="sofaUrl" translatable="false">https://jamanetwork.com/journals/jama/fullarticle/2492881</string>
    <string name="sofaTitle">qSOFA and SOFA score</string>
    <string name="sofaScore">SOFA score</string>
    <string name="fourHundredOrMore" translatable="false">≥400 (53.3)</string>
    <string name="belowFourHundred" translatable="false"><![CDATA[<400 (53.3)]]></string>
    <string name="belowThreeHundred" translatable="false"><![CDATA[<300 (40)]]></string>
    <string name="belowTwoHundred"><![CDATA[<200 (26.7) with respiratory support]]></string>
    <string name="belowOneHundredWithRespiratorySupport"><![CDATA[<100 (13.3) with respiratory support]]></string>
    <string name="oneHundredAndFiftyOrMore">≥150</string>
    <string name="belowOneHundredAndFifty" translatable="false"><![CDATA[<150]]></string>
    <string name="belowOneHundred" translatable="false"><![CDATA[<100]]></string>
    <string name="belowFifty" translatable="false"><![CDATA[<50]]></string>
    <string name="belowTwenty" translatable="false"><![CDATA[<20]]></string>
    <string name="below12" translatable="false"><![CDATA[<1.2 (20)]]></string>
    <string name="between1219" translatable="false">1.2-1.9 (20-32)</string>
    <string name="between2059" translatable="false">2.0-5.9 (33-101)</string>
    <string name="between60119" translatable="false">6.0-11.9 (102-204)</string>
    <string name="above120" translatable="false"><![CDATA[>12.0 (204)]]></string>
    <string name="seventyOrMore" translatable="false">MAP ≥70 mm Hg</string>
    <string name="belowSeventy" translatable="false"><![CDATA[MAP <70 mm Hg]]></string>
    <string name="dopamine5"><![CDATA[Dopamine <5 or dobutamine (any dose)]]></string>
    <string name="dopamine5115">Dopamine 5.1-15 or epinephrine ≤0.1 or norepinephrine ≤0.1</string>
    <string name="dopamine15"><![CDATA[Dopamine >15 or epinephrine >0.1 or norepinephrine >0.1]]></string>
    <string name="fifteen">15</string>
    <string name="between1314">13-14</string>
    <string name="between1012">10-12</string>
    <string name="between69">6-9</string>
    <string name="below6"><![CDATA[<6]]></string>
    <string name="below12Sofa"><![CDATA[<1.2 (110)]]></string>
    <string name="between1219Sofa">1.2-1.9 (110-170)</string>
    <string name="between2034">2.0-3.4 (171-299)</string>
    <string name="between3549">3.5-4.9 (300-440) or urine output &lt;500 mL/d</string>
    <string name="above5Sofa"><![CDATA[>5.0 (440) or urine output <200 ml/d]]></string>
    <string name="sofaCoagulation">Coagulation: platelets, ×10&lt;sup>3&lt;/sup>/μL</string>
    <string name="sofaCardiovascular">Cardiovascular</string>
    <string name="sofaCentralNervousSystem">Central nervous system: Glasgow Coma Scale score</string>
    <string name="qSofaRespiratoryRate">Respiratory rate ≥22/min</string>
    <string name="qSofaAlteredMentation">Altered mentation</string>
    <string name="qSofaSystolicBloodPressure">Systolic blood pressure 100 mm Hg</string>
    <string name="qSofaCriteria">qSOFA (Quick SOFA) Criteria</string>
    <string name="qSofa">qSOFA</string>
    <string name="qSofaScore">qSOFA score</string>
    <string name="sofaLiver">Liver: bilirubin, mg/dL (μmol/L)</string>
    <string name="sofaRespiration">Respiration: PaO&lt;sub>2&lt;/sub>/FIO&lt;sub>2&lt;/sub>, mmHg (kPa)</string>
    <string name="sofaRenal">Renal: creatinine, mg/dL (μmol/L) or urine output, mL/d</string>
    <string name="mapMeanArterialPressure">MAP, mean arterial pressure</string>
    <string name="sofaAndQSofa">SOFA and qSOFA</string>
    <string name="sofaAndQSofaInfo">qSOFA ≥ 2: poor outcomes typical of sepsis.\nIncrease SOFA score from baseline ≥ 2: in-hospital mortality greater than 10%.\nThe baseline SOFA score should be assumed to be zero unless the patient is known to have preexisting (acute or chronic) organ dysfunction before the onset of infection.</string>
    <string name="sepsis">Sepsis</string>
    <string name="shock">Shock</string>
    <string name="map">MAP</string>
    <string name="dpcTitle">DPC算定</string>
    <string name="diseaseNamePlaceholder" translatable="false">MAP</string>

</resources>